

**National Society for Histotechnology - Region IX
Financial Statements**

July 31, 2017

(Unaudited - see Notice to Reader)

Notice To Reader

On the basis of information provided by management, we have compiled the statement of financial position of National Society for Histotechnology - Region IX as at July 31, 2017 and the statements of operations and changes in net assets for the year then ended. We have not performed an audit or a review engagement in respect of these financial statements and, accordingly, we express no assurance thereon. Readers are cautioned that these statements may not be appropriate for their purposes.

Medicine Hat, Alberta

August 22, 2017

MNP LLP

Chartered Professional Accountants

National Society for Histotechnology - Region IX
Statement of Financial Position

As at July 31, 2017
(Unaudited - see Notice to Reader)

	2017	2016
Assets		
Current		
Cash	15,651	15,124
Term deposit	12,060	12,000
	27,711	27,124
Liabilities		
Current		
Accounts payable and accruals	950	950
Unrestricted net assets	26,761	26,174
	27,711	27,124

National Society for Histotechnology - Region IX

Statement of Operations

For the year ended July 31, 2017
(Unaudited - see Notice to Reader)

	2017	2016
Revenue		
Contributions	1,800	3,297
Interest	62	80
	1,862	3,377
Activities and programs		
Education day	-	807
Honorariums and awards	253	622
Website	23	60
	276	1,489
Administrative		
Professional fees	992	992
Bank charges and interest	7	30
	999	1,022
Total expenses	1,275	2,511
Excess of revenue over expenses	587	866

National Society for Histotechnology - Region IX
Statement of Changes in Net Assets

For the year ended July 31, 2017
(Unaudited - see Notice to Reader)

	2017	2016
Unrestricted net assets, beginning of year	26,174	25,308
Excess of revenue over expenses	587	866
Unrestricted net assets, end of year	26,761	26,174
